linjc16/ctgov huggingface dataset:
L-Tyrosine Supplementation in Patients With Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
Patients in the study, who have a diagnosis of fibromyalgia, will be randomly assigned to take the amino acid L-tyrosine or placebo (blank pill) for 3 weeks. They will fill out questionnaires about their symptoms and see if they have any improvement. The investigators hypothesis is that taking tyrosine will help alleviate the symptoms of fibromyalgia.

Detailed Description
-----------------
Fibromyalgia is a chronic pain syndrome with few treatment options available. The amino-acid L-tyrosine is the precursor for norepinephrine in the central nervous system (CNS). Norepinephrine in the CNS has important roles in pain and mood modulation and descending inhibition of pain pathways. By giving the precursor L-tyrosine in high doses we believe that we can increase levels of norepinephrine in the CNS. To study this question we designed a randomized blinded pilot study of 30 patients. Patients are randomly assigned to one of 3 groups (placebo, tyrosine 1000mg/day, and tyrosine 2000mg/day.) for 3 weeks. Patients then complete the Brief Pain Inventory (BPI) daily and the Fibromyalgia impact questionnaire (FIQ) on day 1 and day 21. Patients also complete a drug diary. They are monitored weekly for progress during the study.

Official Title
-----------------
L-Tyrosine Supplementation in Patients With Fibromyalgia

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Drug: Tyrosine
* Drug: Tyrosine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of fibromyalgia Pain greater than 4/10 Age greater than 18 Exclusion Criteria: Pregnant Age less than 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tyrosine 1000 mg / day<br>Patients receive 1000 mg tyrosine per day. | Drug: Tyrosine<br>* 1000 mg / day<br>|
| Experimental: Tyrosine 2000 mg / day<br>Patients receive 2000 mg tyrosine per day. | Drug: Tyrosine<br>* 2000 mg / day<br>|
| Placebo Comparator: Placebo<br>Patients receive placebo daily. | Drug: Placebo<br>* Placebo daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Score |  | daily for 21 days | 
| FIQ Score |  | Day 1 | 
| FIQ Score |  | Day 21 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diet, Fibromyalgia, Pain, Drug, Amino-acid, Fatigue
Post-COVID-19 Pneumo-hematocele

Study Overview
=================
Brief Summary
-----------------
Introduction. As the COVID-19 pandemic has continued, an increasing number of long-term complications are emerging. Recently, the appearance of characteristic pulmonary lesions has been noted, being described as post COVID-19 pneumatocele. The aim of this study is to describe the clinical, histopathologic and imaging features of post COVID-19 pneumo-hematoceles (PHC) and secondarily to suggest a treatment algorithm in these patients. Methods. A retrospective study was performed in patients admitted with diagnosis of SARS-CoV2 infection from March 2020 to September 2021 who presented PHC on imaging studies. Clinical and demographic variables were recorded and CT scans were analyzed. A logistic regression analysis was performed to determine the risk for rupture according to PHC characteristics. It appears that PHC occurs secondary to encapsulation of blood accumulation, the result of micro capillary bleeding, with partial reabsorption of blood and subsequent air filling. The recommendation is to operate on patients with PHC of 5cm and those with persistent lesions of 3cm.

Official Title
-----------------
Post COVID-19 Pneumo-hematocele: Clinical Presentation and Treatment Pathway

Conditions
-----------------
COVID-19 Respiratory Infection

Intervention / Treatment
-----------------
* Procedure: Pulmonary resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with a positive protein chain reaction for SARS-CoV2, PHC on imaging studies. Exclusion Criteria: loss of follow up age out of range.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pneumohematocele<br>Patients with SARS CoV-2 diagnosis and PHC on imaging studies | Procedure: Pulmonary resection<br>* Resection of pneumohematocele<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PHC diagnosis | Pneumohematoceles on imaging studies | From date of diagnosis until 4 weeks after diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Pneumohematocele, Giant bullae, Pneumatocele
Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival

Study Overview
=================
Brief Summary
-----------------
Investigator determined the factor of surgery associated with the survival of pancreatic neuroendocrine tumor.

Detailed Description
-----------------
The variables including clinical characteristics, surgical data and pathological findings are examined by univariate and multivariate analyses.

Official Title
-----------------
Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival

Conditions
-----------------
Pancreatic Neuroendocrine Tumor

Intervention / Treatment
-----------------
* Procedure: pancreatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients with pancreatic neuroendocrine tumor underwent pancreatectomy Exclusion Criteria: The patients with pancreatic neuroendocrine tumor did not undergo pancreatectomy

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The survival rate |  | 3 years |
Semi-quantitative Cough Strength Score (SCSS)

Study Overview
=================
Brief Summary
-----------------
Cough strength score will give true prediction of Extubation outcome

Detailed Description
-----------------
Head trauma patients were evaluated for readiness to be weaned off mechanical ventilation. If they had completed an Spontaneous Breathing Trial (SBT) before extubation. To measure Semiquantitative Cough Strength Score (SCSS), the investigator will put the patients at 30° to 45°, measure SCSS, first. The investigator enhance the patient to cough with as much effort as, when the investigator disconnect the ventilator. The cough strength was scored from 0 to 5 as follows: 0 = no cough on command, 1 = audible movement of air through the endotracheal tube but no audible cough, 2 = weakly (barely) audible cough, 3 = clearly audible cough, 4 = stronger cough and 5 = multiple sequential strong coughs.

Official Title
-----------------
Impact of Semi-quantitative Cough Strength Score as a Strong Predictor for Extubation Outcome in Head Trauma Patients: a Prospective Descriptive Study

Conditions
-----------------
Mechanical Ventilation

Intervention / Treatment
-----------------
* Other: Semiquantitative Cough Strength Score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study included 80 adult male and female patients' their ages between 18-65 years admitted to trauma ICU with head trauma, on mechanical ventilation more than 24 hours and was ready to be weaned off from mechanical ventilation after successful spontaneous breathing trial and Glasgow Coma Scale (GCS) score > 8 before extubation Exclusion Criteria: • Patients who had undergone tracheostomy before extubation, GCS ≤ 8, chest trauma (ribs fracture and lung contusion) and patients with chronic chest disease (Chronic obstructive pulmonary disease, tuberculosis and cancer lung) were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extubation outcome (success or failure), is the patient reintubate again or not and it's correlation with the level of Cough Strength Score | The cough strength was scored from 0 to 5 as follows: 0 = no cough on command, 1 = audible movement of air through the endotracheal tube but no audible cough, 2 = weakly (barely) audible cough, 3 = clearly audible cough, 4 = stronger cough and 5 = multiple sequential strong coughs. | within 6 hours postextubation |
Stent Thrombosis After Tandem Lesions Thrombectomy

Study Overview
=================
Brief Summary
-----------------
The aim is to describe the rate of delayed stent thrombosis after endovascular management of consecutive tandem lesions, in a patient series with systematic follow-up of stent patency. In addition, Investigatros aim to research baseline patient characteristics that are associated with a higher risk of delayed stent thrombosis and to evaluate the clinical consequences of stent thrombosis

Official Title
-----------------
PREDICTEURS ET IMPACT CLINIQUE DE LA THROMBOSE DU STENT APRES LES THROMBECTOMIES CEREBRALES POUR LES OCCLUSIONS EN TANDEM

Conditions
-----------------
Acute Stroke With Large Vessel Occlusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent endovascular treatments for acute ischemic stroke in Strasbourg University Hospitals between 01/01/2009 and 01/04/2018 Association of extracranial internal carotid artery (ICA) occlusion or stenosis ≥70% using NASCET criteria and an intracranial arterial occlusion in the anterior circulation Exclusion Criteria: - Endovascular treatments for complication of surgical carotid endarterectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stent thrombosis rate |  | participants will be followed for the duration of hospital stay, an expected average 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute stroke, thrombectomy, tandem lesions
Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
Patients admitted to the hospital with chronic obstructive pulmonary disease are evaluated with regard to early follow-up by a specialized nurse in the home after discharge.

Detailed Description
-----------------
Patients admitted to Department of Internal Medicine M, Glostrup University hospital, with Chronic Obstructive Pulmonary Disease (COPD) are evaluated with regard to early follow-up by a specialized nurse in the home after discharge. Eligible patients receive education about disease management. The intervention is evaluated by comparing the number of readmissions for COPD and the duration of admissions during the study period to the the period prior to the implementation of this intervention.

Official Title
-----------------
Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Procedure: Patient education and disease management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admission for chronic obstructive pulmonary disease Exclusion Criteria: Other severe acute or chronic diseases
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Patient education and disease management|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of readmissions for chronic obstructive pulmonary disease |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the duration of admissions for chronic obstructive pulmonary disease |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic obstructive pulmonary disease, Outpatient management, nurse-lead patient education
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

Study Overview
=================
Brief Summary
-----------------
To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

Detailed Description
-----------------
Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.

Official Title
-----------------
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

Conditions
-----------------
Bacterial Infections, HIV Infections

Intervention / Treatment
-----------------
* Drug: Azithromycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Antiretroviral agents, provided regimen has been stable for at least 1 month. Patients must have: HIV infection. CD4 count <= 200 cells/mm3. No active opportunistic infection (pending discussion with Pfizer Clinician). Prior Medication: Allowed: Prior antiretroviral agents. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Active intercurrent illness (pending discussion with the Pfizer Clinician). Allergies to macrolide antibiotics. Signs and symptoms of severe illness that would preclude treatment. Patients with the following prior conditions are excluded: History of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. Clinically important change in baseline status within 4 weeks prior to study entry. Condition affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies) within 4 weeks prior to study entry. Prior Medication: Excluded: Investigational drugs including treatment IND drugs within 4 weeks prior to study entry. Known drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Azithromycin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acquired Immunodeficiency Syndrome, Azithromycin, Bacterial Infections
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Study Overview
=================
Brief Summary
-----------------
To determine the feasibility and safety of administering YM155 in combination with docetaxel

Detailed Description
-----------------
This clinical trial is designed to include two parts: Part 1: Assessment of feasibility and safety of administering YM155 in combination with docetaxel and prednisone in subjects with hormone refractory prostate cancer (HRPC) [ ENROLLMENT COMPLETED ] Part 2: Assessment of feasibility and safety of administering YM155 in combination with docetaxel in subjects with solid tumors (except HRPC). This registration has been updated to reflect the design requirements of PART 2.

Official Title
-----------------
A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Conditions
-----------------
Prostate Cancer, Tumors

Intervention / Treatment
-----------------
* Drug: YM 155
* Drug: Docetaxel
* Drug: Prednisone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Part 1: Male subjects with histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease. Part 2: Subjects with histologically and cytologically confirmed solid tumors with measurable disease (except HRPC). Exclusion Criteria: Radiation therapy within 4 weeks of the start of study drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1. HRPC<br> | Drug: YM 155<br>* IV<br>Drug: Docetaxel<br>* IV<br>Drug: Prednisone<br>* Oral<br>|
| Experimental: 2. Solid Tumors<br> | Drug: YM 155<br>* IV<br>Drug: Docetaxel<br>* IV<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC) |  | 2 cycles | 
| Occurrence of dose limiting toxicities (Part 2: Subjects with other solid tumors) |  | 1 cycle | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of safety and efficacy |  | 10 cycles | 
| Assessment of pharmacokinetics |  | Part 1 only | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate Cancer, HRPC, Hormone Refractory Prostate Cancer, YM155, Treatment Outcome, Solid Tumors
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Study Overview
=================
Brief Summary
-----------------
This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting. Patient demographics and characteristics along with the treatments received will be described. Investigators will establish the percentage of patients who undergo surgery, the percentage of patients who are treated with kinase inhibitors as well as in what setting (adjuvant or metastatic) as well as the duration of therapy. Physician information will also be collected to assess for differences in treatment based on physician or geographical differences.

Official Title
-----------------
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting

Conditions
-----------------
Gastrointestinal Stromal Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastrointestinal Stromal Tumors, GIST, tyrosine kinase inhibitors, Imatinib, Gleevec, Suntinib, Sutent